Aspen Neuroscience, Inc., a private biotechnology company developing personalized, autologous cell therapies, has appointed Dalen Meeter, CPA, MBA, as Chief Financial Officer (CFO).
“We are excited to welcome Dalen to our executive team during this significant period of growth and development at Aspen,” said Damien McDevitt, PhD, president and CEO of Aspen Neuroscience. “His financial leadership experience within the biotech sector will be important during our corporate evolution, as we advance our clinical programs and prepare for the future.”
“It is an honor to join this groundbreaking company at such a pivotal time,” said Mr. Meeter. “I look forward to contributing to the company’s mission of developing transformative therapies for patients with Parkinson’s disease.”
With more than two decades of finance and accounting expertise, Dalen brings extensive experience in scaling private and public companies to his new role. Prior to Aspen, most recently he served as CFO of Singular Genomics Systems, Inc. After guiding Singular’s finance transformation from a private, development-stage startup to a publicly traded, commercial-stage company, he then led as CFO of the public entity.
Before joining Singular, Dalen spent many years in Finance leadership at Illumina, as well as in auditing during his time at KPMG. Mr. Meeter holds an undergraduate degree from the University of California, Santa Barbara, and an MBA from the University of Southern California’s Marshall School of Business.